luspatercept-aamt (Reblozyl)
Jump to navigation
Jump to search
Indications
- beta-thalassemia
- myelodysplastic syndrome after epoietin-alfa failure[3]
Dosage
- 1 mg/kg SC every 3 weeks
Injection: 75 mg lyophilized powder in a single-dose vial
Adverse effects
Mechanism of action
- recombinant fusion protein that binds several endogenous TGF-beta superfamily ligands, thus diminishing Smad2/3 signaling
- promotes erythroid maturation through differentiation of normoblasts in mice.
More general terms
References
- ↑ RxNorm
- ↑ FDA Drug Approval. Nov 8m 2019 FDA approves luspatercept-aamt for anemia in patients with beta thalassemia. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-luspatercept-aamt-anemia-patients-beta-thalassemia
- ↑ 3.0 3.1 European Society of Medical Oncology Myelodysplastic Syndromes Clinical Practice Guidelines (ESMO, 2021) Medscape - Feb 03, 2021. https://reference.medscape.com/viewarticle/944879
- ↑ Highlights of Prescribing Information. REBLOZYL (luspatercept-aamt) for injection, for subcutaneous use https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761136lbl.pdf